Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BACTAF: TAF vs Abacavir for TDF-related Renal Toxicity
NCT02957864Phase 4Unknown
- Sponsor
- Erasmus MC
- Start
- Oct 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Erasmus MC. Primary endpoint: Recovery of renal dysfunction at 48 weeks. Status: unknown.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02957864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957864.